• 1
    World Health Organization. The Atlas of Heart Disease and Stroke. Geneva: World Health Organization; 2004.
  • 2
    Brown DL, Lisabeth LD, Roychoudhury C, et al. Recurrent stroke risk is higher than cardiac event risk after initial stroke/transient ischemic attack. Stroke. 2005;36:12851287.
  • 3
    Arima H, Tzourio C, Butcher K, et al. Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial. Stroke. 2006;37:14971502.
  • 4
    Adams RJ, Chimowitz MI, Alpert JS, et al. Coronary risk evaluation in patients with transient ischemic attack and ischemic stroke: a scientific statement for healthcare professionals from the Stroke Council and the Council on Clinical Cardiology of the American Heart Association/American Stroke Association. Stroke. 2003;34:23102322.
  • 5
    Kokmen E, Whisnant JP, O’Fallon WM, et al. Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960-1984). Neurology. 1996;46:154159.
  • 6
    Pohjasvaara T, Erkinjuntti T, Vataja R, et al. Dementia three months after stroke. Baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort. Stroke. 1997;28:785792.
  • 7
    World Health Organization. Preventing Chronic Disease: a Vital Investment. Geneva: World Health Organization; 2005.
  • 8
    Lawes CM, Vander Hoorn S, Rodgers A, et al. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:15131518.
  • 9
    PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:10331041.
  • 10
    Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:15271535.
  • 11
    PATS Collaborating Group. Post-stroke antihypertensive treatment study: a preliminary result. Chin Med J. 1995;108:710717.
  • 12
    The INDANA (INdividual Data ANalysis of Antihypertensive intervention trials) Project Collaborators. Effect of antihypertensive treatment in patients having already suffered from stroke: gathering the evidence. Stroke. 1997;28:25572562.
  • 13
    PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J. 2003;24:475484.
  • 14
    PROGRESS Collaborative Group. Effects of a perindopril-based blood pressure-lowering regimen on disability and dependency in 6105 patients with cerebrovascular disease: a randomized controlled trial. Stroke. 2003;34:23332338.
  • 15
    Tavakoli M, Pumford N, Woodward M, et al. An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event. Eur J Health Econ. 2009;10:111119.
  • 16
    Chapman N, Huxley R, Anderson C, et al. Effects of a perindopril-based blood pressure lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS trial. Stroke. 2004;35:116121.
  • 17
    Arima H, Tzourio C, Anderson C, et al. Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial. Stroke. 2010;41:394396.
  • 18
    Skoog I, Lernfelt B, Landahl S, et al. 15-year longitudinal study of blood pressure and dementia. Lancet. 1996;347:11411145.
  • 19
    Tzourio C, Dufouil C, Ducimetiere P, et al. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology. 1999;53:19481952.
  • 20
    Tzourio C, Anderson C, Chapman N, et al. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med. 2003;163:10691075.
  • 21
    Dufouil C, Chalmers J, Coskun O, et al. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation. 2005;112:16441650.
  • 22
    Dufouil C, Godin O, Chalmers J, et al. Severe cerebral white matter hyperintensities predict severe cognitive decline in patients with cerebrovascular disease history. Stroke. 2009;40:22192221.
  • 23
    Rodgers A, Chapman N, Woodward M, et al. Perindopril-based blood pressure lowering in individuals with cerebrovascular disease: consistency of benefits by age, sex and region. J Hypertens. 2004;22:653659.
  • 24
    Arima H, Anderson C, Omae T, et al. Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. J Hypertens. 2010;28:395400.
  • 25
    Czernichow S, Ninomiya T, Huxley R, et al. Impact of blood pressure lowering on cardiovascular outcomes in normal weight, overweight, and obese individuals: the Perindopril Protection Against Recurrent Stroke Study trial. Hypertension. 2010;55:11931198.
  • 26
    Berthet K, Neal BC, Chalmers JP, et al. Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS trial. Blood Press. 2004;13:713.
  • 27
    Arima H, Hart RG, Colman S, et al. Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke. 2005;36:21642169.
  • 28
    Perkovic V, Ninomiya T, Arima H, et al. Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study. J Am Soc Nephrol. 2007;18:27662772.
  • 29
    Arima H, Anderson C, Omae T, et al. Effects of blood pressure lowering on major vascular events among patients with isolated diastolic hypertension: the PROGRESS trial. Stroke. 2011;42:23392341
  • 30
    Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:19031913.
  • 31
    Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular diseases in the Asia-Pacific region. J Hypertens. 2003;21:707716.
  • 32
    Rodgers A, MacMahon S, Gamble G, et al. Blood pressure and risk of stroke in patients with cerebrovascular disease. BMJ. 1996;313:147.
  • 33
    Arima H, Chalmers J, Woodward M, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens. 2006;24:12011208.
  • 34
    Ninomiya T, Perkovic V, Gallagher M, et al. Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. Kidney Int. 2008;73:963970.
  • 35
    The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:15751585.
  • 36
    Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:12061252.
  • 37
    Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) of the European Society of Cardiology (ESC). J Hypertens. 2007;25:11051187.
  • 38
    Turan TN, Cotsonis G, Lynn MJ, et al. Relationship between blood pressure and stroke recurrence in patients with intracranial arterial stenosis. Circulation. 2007;115:29692975.
  • 39
    Rothwell PM, Howard SC, Spence JD, et al. Relationship between blood pressure and stroke risk in patients with symptomatic carotid occlusive disease. Stroke. 2003;34:25832592.
  • 40
    Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomised controlled study (MOSES). Stroke. 2005;36:12181226.
  • 41
    Trenkwalder P, Elmfeldt D, Hofman A, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroups of patients. Blood Press. 2005;14:3137.
  • 42
    Liu L, Wang Z, Gong L, et al. Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res. 2009;32:10321040.
  • 43
    Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med. 2008;359:12251237.
  • 44
    Dahlöf B, Sever PS, Poulter NR, et al; for the ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895906.
  • 45
    Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:15451553.
  • 46
    The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145153.
  • 47
    Dahlöf B, Devereux R, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:9951003.
  • 48
    The Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372:11741183.